Intra-Cellular Therapies saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 67 to 75.
IBD's unique rating tracks price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks often have an 80 or better RS Rating in the early stages of their moves. See if Intra-Cellular Therapies can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Intra-Cellular Therapies is building a cup with handle with an 82.00 entry. See if it can clear the breakout price in heavy volume.
Intra-Cellular Therapies reported 0% earnings growth last quarter. Sales rose 46%. The company is expected to report its latest numbers on or around Oct. 30.
Intra-Cellular Therapies holds the No. 47 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and United Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
